Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study - Concepedia

Concepedia

Publication | Closed Access

Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

140

Citations

27

References

2013

Year

Joo Ern Ang, Charlie Gourley, C. Bethan Powell, Hilda A. High, Ronnie Shapira‐Frommer, Vincent Castonguay, Jacques De Grève, Tina Atkinson, Timothy A. Yap, Shahneen Sandhu,

Clinical Cancer Research

Abstract

Heavily pretreated PBMCOC who are PARPi-resistant retain the potential to respond to subsequent chemotherapy, including platinum-based agents. These data support the further development of PARPi in PBMCOC.

References

	Year	Citations

Page 1